Ultragenyx Pharmaceu (RARE)

$24.57 +0.94 (3.98%)
Market Cap 2.32B
Revenue (ttm) 673.00M
Net Income (ttm) -575.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -85.44%
Debt to Equity Ratio 0.00
Volume 1,820,000
Avg Vol 2,167,232
Day's Range N/A - N/A
Shares Out 98.31M
Stochastic %K 96%
Beta 0.25
Analysts Strong Sell
Price Target $52.45

Company Profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevi...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 483 8800
Address:
60 Leveroni Court, Novato, United States
Biologics
Biologics Apr. 12 at 12:59 PM
My recent article on $RARE https://seekingalpha.com/article/4890075-ultragenyx-pharmaceutical-the-market-is-overlooking-2026-catalysts?source=copy_to_clipboard
0 · Reply
ClinicalTrialsDaily
ClinicalTrialsDaily Apr. 9 at 8:36 PM
$RARE Phase 3 Enh3ance hits primary endpoint: 18% ammonia reduction vs placebo (p=0.018) with 27% scavenger taper. One placebo death, zero treated. 64-week treatment burden data H1 2027 — that's the BLA readout. Pricing at $2.5-3.2M justified against $500K-1M/yr Ravicti. TAM ~250-300 patients limits peak revenue but PRV ($95-110M) de-risks near-term. Read more: www.clinicaltrialsdaily.com/ultragenyx-dtx301-phase-3-otc-deficiency/
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 9 at 1:42 PM
$OMER there's no way $RARE IS WORTH MORE THAN THIS COMPANY
0 · Reply
QuantInsider
QuantInsider Apr. 3 at 2:08 AM
$RARE popping off today, up 4.81% and 12.25% over the past 5 days FDA's nod on the UX111 BLA and UX016 IND is a big deal, driving that momentum Options flow is all about those May $20 puts, around 636 contracts, no sweeps Traders seem to be hedging their bets, not going all in on upside Feels like a cautious vibe, keeping an eye on volatility after the spike Might be smart to stick with defined risk plays here
0 · Reply
STACKD0E
STACKD0E Apr. 2 at 2:20 PM
$RARE $LPCN
0 · Reply
jaykza
jaykza Apr. 2 at 1:46 PM
$ABEO Double good news a $RARE UX-111 BLA submission accepted as well.
2 · Reply
TwongStocks
TwongStocks Apr. 2 at 12:32 PM
$RARE Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) https://www.globenewswire.com/news-release/2026/04/02/3267337/20739/en/Ultragenyx-Announces-U-S-FDA-Acceptance-of-BLA-Resubmission-for-UX111-AAV-Gene-Therapy-to-Treat-Sanfilippo-Syndrome-Type-A-MPS-IIIA.html • PDUFA action date set for September 19, 2026
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 1 at 2:33 AM
$RARE Share Price: $20.93 Contract Selected: Nov 20, 2026 $20 Calls Buy Zone: $5.61 – $6.93 Target Zone: $10.43 – $12.74 Potential Upside: 76% ROI Time to Expiration: 233 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
StockBen4444
StockBen4444 Mar. 31 at 4:41 PM
$RARE can i see a bull flag?
0 · Reply
StockBen4444
StockBen4444 Mar. 30 at 5:26 PM
$RARE think 30$ in some time is possible!
0 · Reply
Latest News on RARE
DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors to Contact the Firm Before April 6, 2026

Apr 3, 2026, 9:43 AM EDT - 11 days ago

DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors to Contact the Firm Before April 6, 2026

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy

Mar 30, 2026, 8:30 AM EDT - 15 days ago

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy

Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ: RARE) Investors of the Upcoming April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm

Mar 25, 2026, 4:10 PM EDT - 20 days ago

Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ: RARE) Investors of the Upcoming April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 20, 2026, 4:30 PM EDT - 25 days ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder

Mar 12, 2026, 1:35 PM EDT - 4 weeks ago

Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder

Ultragenyx's gene therapy helps control ammonia levels in late-stage study

Mar 12, 2026, 8:47 AM EDT - 4 weeks ago

Ultragenyx's gene therapy helps control ammonia levels in late-stage study

Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Feb 24, 2026, 9:11 AM EST - 7 weeks ago

Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Ultragenyx to Participate at Investor Conferences in March

Feb 23, 2026, 4:30 PM EST - 7 weeks ago

Ultragenyx to Participate at Investor Conferences in March

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Feb 23, 2026, 8:30 AM EST - 7 weeks ago

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE

Feb 18, 2026, 2:07 PM EST - 7 weeks ago

Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE

Why Is Ultragenyx Stock Sinking Friday?

Feb 13, 2026, 1:21 PM EST - 2 months ago

Why Is Ultragenyx Stock Sinking Friday?

Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Feb 12, 2026, 4:01 PM EST - 2 months ago

Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical

Feb 9, 2026, 4:30 PM EST - 2 months ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit

Feb 9, 2026, 3:01 AM EST - 2 months ago

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)

Feb 3, 2026, 8:00 AM EST - 2 months ago

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

Jan 30, 2026, 8:30 AM EST - 2 months ago

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies

Jan 23, 2026, 2:05 PM EST - 2 months ago

Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

Jan 12, 2026, 7:30 AM EST - 3 months ago

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Dec 30, 2025, 4:05 PM EST - 3 months ago

Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm

Dec 30, 2025, 2:24 PM EST - 3 months ago

Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm

Ultragenyx Bone Drug Stumbles In Phase 3, But Key Catalysts Remain

Dec 30, 2025, 9:52 AM EST - 3 months ago

Ultragenyx Bone Drug Stumbles In Phase 3, But Key Catalysts Remain

These biotech stocks are getting hammered by shocking brittle-bone treatment study results

Dec 29, 2025, 1:05 PM EST - 3 months ago

These biotech stocks are getting hammered by shocking brittle-bone treatment study results

MREO

Ultragenyx's bone disease drug fails late-stage trials

Dec 29, 2025, 8:35 AM EST - 3 months ago

Ultragenyx's bone disease drug fails late-stage trials

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Dec 29, 2025, 8:30 AM EST - 3 months ago

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Nov 4, 2025, 4:01 PM EST - 5 months ago

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

Oct 28, 2025, 4:30 PM EDT - 6 months ago

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

Sep 30, 2025, 4:05 PM EDT - 7 months ago

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Sep 8, 2025, 4:05 PM EDT - 7 months ago

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx to Participate at Investor Conferences in September

Aug 29, 2025, 4:30 PM EDT - 8 months ago

Ultragenyx to Participate at Investor Conferences in September

Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Aug 18, 2025, 8:00 AM EDT - 8 months ago

Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

Aug 5, 2025, 4:01 PM EDT - 9 months ago

Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update

Jul 30, 2025, 8:30 AM EDT - 9 months ago

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update

Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks

Jul 28, 2025, 1:16 PM EDT - 9 months ago

Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks

RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm

Jul 18, 2025, 3:07 PM EDT - 9 months ago

RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Jul 14, 2025, 8:14 AM EDT - 9 months ago

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session

AAPL

Biologics
Biologics Apr. 12 at 12:59 PM
My recent article on $RARE https://seekingalpha.com/article/4890075-ultragenyx-pharmaceutical-the-market-is-overlooking-2026-catalysts?source=copy_to_clipboard
0 · Reply
ClinicalTrialsDaily
ClinicalTrialsDaily Apr. 9 at 8:36 PM
$RARE Phase 3 Enh3ance hits primary endpoint: 18% ammonia reduction vs placebo (p=0.018) with 27% scavenger taper. One placebo death, zero treated. 64-week treatment burden data H1 2027 — that's the BLA readout. Pricing at $2.5-3.2M justified against $500K-1M/yr Ravicti. TAM ~250-300 patients limits peak revenue but PRV ($95-110M) de-risks near-term. Read more: www.clinicaltrialsdaily.com/ultragenyx-dtx301-phase-3-otc-deficiency/
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 9 at 1:42 PM
$OMER there's no way $RARE IS WORTH MORE THAN THIS COMPANY
0 · Reply
QuantInsider
QuantInsider Apr. 3 at 2:08 AM
$RARE popping off today, up 4.81% and 12.25% over the past 5 days FDA's nod on the UX111 BLA and UX016 IND is a big deal, driving that momentum Options flow is all about those May $20 puts, around 636 contracts, no sweeps Traders seem to be hedging their bets, not going all in on upside Feels like a cautious vibe, keeping an eye on volatility after the spike Might be smart to stick with defined risk plays here
0 · Reply
STACKD0E
STACKD0E Apr. 2 at 2:20 PM
$RARE $LPCN
0 · Reply
jaykza
jaykza Apr. 2 at 1:46 PM
$ABEO Double good news a $RARE UX-111 BLA submission accepted as well.
2 · Reply
TwongStocks
TwongStocks Apr. 2 at 12:32 PM
$RARE Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) https://www.globenewswire.com/news-release/2026/04/02/3267337/20739/en/Ultragenyx-Announces-U-S-FDA-Acceptance-of-BLA-Resubmission-for-UX111-AAV-Gene-Therapy-to-Treat-Sanfilippo-Syndrome-Type-A-MPS-IIIA.html • PDUFA action date set for September 19, 2026
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 1 at 2:33 AM
$RARE Share Price: $20.93 Contract Selected: Nov 20, 2026 $20 Calls Buy Zone: $5.61 – $6.93 Target Zone: $10.43 – $12.74 Potential Upside: 76% ROI Time to Expiration: 233 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
StockBen4444
StockBen4444 Mar. 31 at 4:41 PM
$RARE can i see a bull flag?
0 · Reply
StockBen4444
StockBen4444 Mar. 30 at 5:26 PM
$RARE think 30$ in some time is possible!
0 · Reply
DonCorleone77
DonCorleone77 Mar. 30 at 1:23 PM
$RARE Ultragenyx announces FDA clearance of UX016 investigational new drug application Ultragenyx announced that the FDA has cleared the investigational new drug application for UX016, an investigational small molecule prodrug of sialic acid being evaluated as a substrate replacement therapy for GNE myopathy. The UX016 program is externally funded by a patient group through clinical proof-of-concept, including a Phase 1/2 study expected to begin in the second half of 2026.
0 · Reply
anachartanalyst
anachartanalyst Mar. 24 at 6:02 PM
$RARE https://anachart.com/wp-content/uploads/ana_temp/1774375295_soc-img.jpg
1 · Reply
erevnon
erevnon Mar. 24 at 5:38 PM
Goldman Sachs downgrades Ultragenyx Pharmaceutical $RARE from Buy to Neutral and lowers the price target from $61 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
lonelywarrior
lonelywarrior Mar. 24 at 2:42 PM
$RARE Those "analysts" are the last people to know what's going on. They are always off and by a lot.
1 · Reply
SirBioAlot
SirBioAlot Mar. 24 at 2:22 PM
$ACHV interesting setup ahead of June 20 PDUFA. two positive Phase 3 trials, solid safety profile, potential first new smoking cessation therapy in 20 years. Breakthrough Therapy + Commissioner's National PV for vaping on top. but today's earnings added real risk — going concern warning, Sopharma manufacturing dispute, FDA GMP observations on current manufacturer. manufacturing CRLs are a real thing. and even with approval, launch now pushed to H1 2027. honestly at current prices i find $ARVN and $RARE more compelling PDUFA plays. ARVN trades near cash value (~$685MM cash vs ~$860MM mktcap) with vepdegestrant NDA under FDA review, June 5 PDUFA, Phase 3 NEJM-published data — you get the whole PROTAC platform essentially for free. RARE DTX401 PDUFA August 23 with PR strong Phase 3 data &no prior CRL. ACHV has the narrative but the risk/reward feels less clean right now compared to those two. watching but maybe not adding here not financial advice — just my own view. do your own research.
0 · Reply
Bovan
Bovan Mar. 24 at 2:11 PM
$RARE it’s more like Goldman sucks , they are always wrong on their bio research , I’m back in
1 · Reply
SirBioAlot
SirBioAlot Mar. 24 at 1:52 PM
$RARE In! Super interesting.
1 · Reply
notreload_ai
notreload_ai Mar. 24 at 1:47 PM
Goldman Sachs downgraded $RARE from Buy to Neutral and slashed its price target to $25 after setrusumab Phase 3 miss in osteogenesis imperfecta. GTX-102 in Angelman syndrome now key focus, but risks remain. https://notreload.xyz/goldman-sachs-downgrades-ultragenyx-to-neutral-after-setrusumab-trial-miss/
0 · Reply
SkinnyDipping
SkinnyDipping Mar. 23 at 6:39 PM
In Japan, $RARE just received approval of Dojolvi in Japan for the treatment of long-chain fatty acid oxidation disorders. … And shorts aren’t ready.
0 · Reply
TradeHawk
TradeHawk Mar. 23 at 6:30 PM
$RARE Ultragenyx has received approval of Dojolvi in Japan for the treatment of long-chain fatty acid oxidation disorders. https://www.mhlw.go.jp/hourei/doc/tsuchi/T260323I0030.pdf
0 · Reply
ppl_first
ppl_first Mar. 23 at 10:46 AM
$RARE Bottom line RARE is falling because: 1. Guidance disappointed 2. Pipeline credibility weakened 3. Costs being cut 4. No near-term catalyst to fix the story
0 · Reply
PARA_85
PARA_85 Mar. 18 at 7:47 PM
$RARE in
0 · Reply